About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Fish Oil, Metformin and Heart Health in PCOS | Clinical Trials | Clareo Health

RECRUITINGPhase 1

Fish Oil, Metformin and Heart Health in PCOS

Dietary Fish Oil and Metformin Intervention for Heart Health in PCOS

NCT06424860•University of Alberta

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

PCOSCardiovascular DiseaseAtherosclerotic Cardiovascular Disease+2 more

Interventions

Fish oil

Metformin

+1 more

Locations

3

Canada

Locations (3)

Human Nutrition Research Unit - Li Ka Shing Health Research Center

Edmonton, Alberta, Canada

Mazankowski Alberta Heart Institute

Edmonton, Alberta, Canada

University of Alberta Hospital - Division of Endocrinology

Edmonton, Alberta, Canada

Key Dates

Start Date

November 1, 2025

Primary Completion Date

December 30, 2026

Completion Date

December 30, 2027

Last Updated

December 12, 2025

Related Studies

Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome

NCT07547098

Cardiovascular Diseases (CVD)Chronic Kidney Disease+2 more

Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany

NCT06675552

Heart DiseaseHeart Failure+2 more

Is Post-exertional Symptom Exacerbation Specific to Patients With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome? A Study Comparing Patients With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome and Patients With Cardiac Diseases Who Underwent an Exercise Test.

NCT07491315

Fatigue Syndrome, ChronicCardiovascular Diseases

RECRUITINGPhase 1/2

TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

NCT07487363

Atherosclerotic Cardiovascular DiseasesEndothelial Dysfunction

Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry

NCT07256249

Cardiovascular Diseases

RECRUITINGPhase 3

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390

Atherosclerosis Cardiovascular DiseaseChronic Kidney Disease

View all related studies

Contacts

Donna Vine, PhD

CONTACT

780-492-4393 dvine@ualberta.ca

Sponsors

Lead Sponsor

University of Alberta

Collaborators

Heart and Stroke Foundation of Canada

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 12, 2025Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions